Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06840106
Recruiting Not applicable

Nasal Steam Therapy for Post-extubation Respiratory Events

NCT06840106 · tracked via the Priya Life Science South Korea tracker
Sponsor
Ilsan Cha hospital
Phase
Not applicable
Started
2025-02-18
Last updated
2025-04-02

Condition(s) studied

Thyroid CancerIntubation

Investigational drug(s) / intervention(s)

Nasal steam therapyRoutine management strategy

Nasal steam therapy: Nasal steam therapy is performed once a every other day for a total of 3three times. The steam inhalation stimulates the acupoints of bilateral LI20, EX-HN8, and EX-HN9

Routine management strategy: Depending on the patient's symptoms and degree of improvement, the clinician may utilize all drugs currently used in clinical practice to improve upper respiratory symptoms, if necessary. All drugs that fall under the Anatomical Therapeutic Chemical Classification System (ATC) codes of non-disease treatment (R01), throat disease treatment (R02), lung disease or expectorant (R03, R05), and other respiratory organ drugs (R06, R07) and other drugs. The usage and dosage should be within the range of the current clinical guidelines.

Study summary

The effect of symptom improvement of nasal steam strategy compared to routine management strategy for upper respiratory symptoms occurring after endotracheal intubation in patients aged 19 years or older who underwent surgical removal under anesthesia requiring endotracheal intubation was evaluated by the difference in the results of Wisconsin Upper Respiratory Symptom Survey

Eligibility

Sex
ALL
Min age
19 Years
Max age
69 Years
Healthy volunteers
No
Inclusion Criteria: * Age of 19 to 69 years * Those who underwent surgical removal of the thyroid gland under endotracheal intubation due to a thyroid tumor * American Society of Anesthesiologists (ASA) status I or II * Those who developed upper respiratory symptoms after surgery ⑤ Voluntarily decided to participate in this clinical trial and signed the informed consent form Exclusion criteria: * Those diagnosed with symptomatic gastroesophageal reflux disease * Chronic cough lasting for more than 3 months prior to surgery, including bronchial asthma and chronic obstructive pulmonary disease (COPD) * Those who developed other respiratory infections within the past month ④ Those who are taking or are required to take other medications that may interfere with the interpretation of the treatment effect or results * Those who are scheduled to undergo additional major treatments such as reoperation, chemotherapy, and radiotherapy during the clinical trial period ⑥ Pregnant women, breastfeeding women, and those who plan to become pregnant during the study period ⑦ Others who are expected to have difficulty complying with the treatment, visits, and questionnaires stipulated in this protocol at the discretion of the medical staff

Primary outcome measure(s)

  • Wisconsin upper respiratory symptom survey-24, WURSS-24 — From enrollment to the end of treatment at Day 8, and follow up visit at Day 15
    WURSS is a questionnaire mainly used to evaluate symptoms of acute upper respiratory tract infection, and is divided into WURSS-11, WURSS-21, WURSS-24, WURSS-44, and WURSS-Kids versions. In this study, WURSS-24 will be used to evaluate the degree of daily symptom improvement by dividing it into items of symptoms, quality of life, and overall satisfaction, and 24 questions on a 7-point Likert scale. The most severe level is evaluated as 7 points, the least level as 1 point, and in the case of symptoms and quality of life that may be lost, 0 points are additionally recorded when the symptoms are lost.

Trial sites (1)

FacilityCityRegionStatus
Ilsan Cha Hospital Goyang-si Gyeonggi-do Recruiting

More Ilsan Cha hospital trials in South Korea

Pharmacopuncture for Aromatase Inhibitor Induced Arthralgia (AIA) Recruiting
Viscum Album for TNBC on Adjuvant Pembrolizumab Recruiting
Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery Starting soon
An Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T) Recruiting

Other trials for the same condition

Active Surveillance for Low-risk Papillary Thyroid Carcinoma Enrolling by invitation
An Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T) Recruiting
Active Surveillance on Papillary Thyroid Microcarcinoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06840106 on ClinicalTrials.gov ↗ ← All trials in South Korea